JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 103 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,146,000 | +36.3% | 137,300 | +21.3% | 0.77% | +22.5% |
| Q3 2021 | $841,000 | +118.4% | 113,200 | +100.0% | 0.63% | +109.3% |
| Q2 2021 | $385,000 | -23.8% | 56,600 | +15.0% | 0.30% | -27.9% |
| Q1 2021 | $505,000 | +46.8% | 49,200 | 0.0% | 0.42% | +35.2% |
| Q4 2020 | $344,000 | -17.7% | 49,200 | -3.9% | 0.31% | -20.7% |
| Q3 2020 | $418,000 | +40.7% | 51,200 | +19.1% | 0.39% | +47.0% |
| Q2 2020 | $297,000 | – | 43,000 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |